13:00
Chairperson’s Opening Remarks
Chen Guang, Consultant, Agency for Science, Technology and Research (A*STAR), Singapore
Joint Opening Plenary
13:10
Keynote Address:
China’s Big Leap towards BioPharma 2030 – Innovation, Industrialization, Internationalization
Dr. Song Ru Lin, Executive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA), China
13:30
Venture Capitals’ Roundtable:
Show Me the Drug
- Investment landscape in the Chinese biopharma market
- Evaluating drug pipelines and development prospects
- Mergers, expansion and JVs – Where do we see transactions picking up?
- Financing new plants, new therapeutics, product launch and scaling-up operations – How do we review?
- Manufacturing 4.0 – How do VCs and banks play a part in modernising the value chain?
Moderator:
Judith Li, Partner, Lilly Asia Ventures, China
Panelists:
Rani Jarkas, Chairman, Cedrus Group, Hong Kong
Lynn Yang, Managing Director, Sequoia Capital, China
Michael Xue, Managing Director, Morningside Ventures, China
14:15
Industry Spotlight:
Addressing Complex Protein Challenges with Lonza’s GS Xceed® Toolbox
Dr. Allison Porter, Head of Expression System Sciences, Lonza Pharma & Biotech, U.K.
14:45
Online Networking & Stretch Break
End of Joint Opening Plenary and 2nd Cell & Gene Therapy Manufacturing commences
China Market
15:00
Chairperson’s Opening Remarks
15:00
Case Study: Tumor-infiltrating Lymphocyte Development
- Development of potential candidates
- Managing China’s cell therapy landscape
Liu Yarong, Chief Executive Officer, Grit Therapeutics, China
15:30
The Case of Solid Tumors:
From Liquid to Solid Tumors, from Manual to Automatic Manufacturing
- Product differentiation: solid tumor advantages
- Overcoming challenges of targeting solid tumors
Dr Zhang Yu, Senior Vice President and Chief Scientific Officer, Vcanbio Cell&Gene Engineering, China
16:00
Chairperson’s Summary and End of Day 1